ChamberlainD. A.MuirD. C. E.KennedyK. P. (1962). Atropine methonitrate and isoprenaline in bronchial asthma. Lancet, 2, 1019
2.
FishelC. W.SzentivanyiA.TalmageD. W. (1962). Sensitisation and desensitisation of mice to histamine and serotonin by neurohumors. J. Immunol., 89, 8
3.
HumeK. M.GandeviaB. (1957). Forced expiratory volume before and after isoprenaline. Thorax, 12, 276
4.
KennedyM. C. S.JacksonS. L. D. (1963). Oral sympathominatic amines in the treatment of asthma. Brit. med. J., 2, 1507
5.
KerrJ. W. (1964). Identification of histamine metabolite 1-methyl, 4-imidazole acetic acid in human urine and its absence in status asthmaticus. Brit. med. J., 2, 606
6.
KnowlesJ. P. (1962). Difficulties in weaning in steroid treatment of asthma. Brit. med. J., 2, 1396
7.
LockettMary F., (1965). Dangerous effects of isoprenaline in myocardial failure. Lancet, 2, 104
8.
MathovE. (1963). The risks of monoamine oxidase inhibitors in the treatment of bronchial asthma. J. Allergy, 34, 483
9.
Medical Research Council (1956). Controlled trial of effects of cortisone acetate in chronic asthma. Lancet, 2, 798
10.
McManisA. G. (1964). Adrenaline and isoprenaline: A warning. Med. J. Aust., 2, 76
11.
McNeillR. S. (1964). Effect of β adrenergic-blocking agent propranolol in asthmatics. Lancet, 2, 1101
12.
SolomonL. M.WentzelH. E.TulskyE. (1964). The physiological disposition of C14-norephinephrene in patients with atopic dermatitis and other dermatosis. J. Invest. Dermat., 34, 193
